Pharmacological options for the protection of ovarian function in patients undergoing chemotherapy by Botha, Matthys Hennie
27
Review: Pharmacological options for the protection of ovarian function in patients undergoing chemotherapy
2015 Vol 7 No 1South Afr J Gynaecol Oncol
Botha MH, MBChB, MMed(O&G), FCOG(SA), PhD 
Associate Professor and Head, Unit for Gynaecological Oncology, Department of Obstetrics and Gynaecology
Faculty of Medicine and Health Sciences, University of Stellenbosch, Tygerberg
Correspondence to: Matthys Botha, e-mail: mhbotha@sun.ac.za
Keywords: protection of ovarian function, pharmacological options, chemotherapy, radiotherapy
Pharmacological options for the protection of ovarian 
function in patients undergoing chemotherapy
Introduction
Over the last few decades, major improvements have 
been made in the treatment of childhood and adolescent 
malignancies. However, treatment modalities may have 
serious harmful effects on ovarian function. Also, the 
incidence of premature ovarian failure (POF) in patients who 
have received chemotherapy and/or radiotherapy is much 
increased when compared to the general population.1,2 
The late effects of cancer treatment have been a popular 
topic for discussion in the medical literature, and various 
attempts has been made to protect young women against 
the potential harm of chemotherapy and radiotherapy. 
Freezing germ cells has improved significantly in the last two 
decades. Oocyte cryopreservation before oncotherapy may 
offer hope, although the success of this technique is often 
limited by the number of available oocytes after stimulation, 
and the availability of time for ovarian stimulation.3 Embryo 
freezing may be another option in women with a male 
partner at the time.
Ovarian tissue cryopreservation may be the only option 
for some young women before they undergo aggressive 
chemotherapy or a combination of chemotherapy and 
radiotherapy.4 This technique is still regarded by many 
experts as experimental, but successful pregnancies have 
been reported from thawed, previously cryopreserved, 
ovarian tissue.5 
This review will focus on hormonal manipulation during 
chemotherapy.
Age at treatment
The age of the patient at the time of treatment with 
chemotherapy remains one of the most important 
determinants of the incidence of ovarian failure. The risk 
increases with age of exposure, and increasing age is as 
an important predictive factor for chemotherapy-induced 
amenorrhoea.6-8
Many theories have been put forward to explain the age 
phenomenon. A popular theory is that the absolute number 
of primordial follicles decreases with age, as demonstrated 
by the Faddy-Gosden differential equation.9-11 It is argued 
that a constant fraction of the primordial follicles is damaged 
during a particular cycle of chemotherapy or radiotherapy. 
Therefore, the remaining number is directly proportional to 
the initial population. The initial pretreatment population of 
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oocytes decreases at a logarithmic rate with increasing age. 
The total number of oocytes in the ovary is a combination of 
primordial, small primary and intermediary follicles.12 
Prepubescent girls are less likely to develop POF after 
chemotherapy than older patients. This finding has led to 
the assumption that the creation of an artificial prepubertal 
environment might lead to ovarian protection. This 
argument has not been conclusively shown in experimental 
models. The reason why younger girls may have less obvious 
functional damage is likely to be owing to the fact that the 
total number of available follicles is much higher at a younger 
age. This argument is supported by the long-term follow-up 
of young girls after receiving chemotherapy, who eventually 
developed premature menopause.13 The relative risk of early 
menopause in the third decade was 9.2 after treatment with 
alkylating agents in a large post-treatment follow-up study.14 
Gonadotrophin-releasing hormone agonists 
Almost 30 years ago, Glode, Robinson and Gould 
tested the possibility of testicular protection against 
cyclophosphamide-induced damage in male mice, and 
found a protective effect of gonadotrophin-releasing 
hormone (GnRH) agonists.15Ataya demonstrated that 
GnRH agonists may protect against chemotherapy-
induced ovarian compromise in a murine model as early 
as 1985. Other animal studies seemed to confirm this 
work.16-19 However, conflicting results from Letterie did not 
show an improvement in outcome.20 Mice treated with 
cyclophosphamide also received combined oestrogen and 
progesterone or leuprolide in this study. Neither method 
of ovulation suppression protected the mice against 
gonadal toxicity. Despite the promising work in rats where 
GnRH agonists inhibited chemotherapy-induced ovarian 
damage, many authors remain sceptical of its application in 
humans.21,22 
It was demonstrated in further animal studies on rhesus 
macaque monkeys (Macaca mulatta) treated with GnRH 
agonists during chemotherapy that more primordial 
follicles remained after treatment in those receiving a GnRH 
agonist.23
The possible protective mechanisms postulated were:
•	 Suppression of the levels of gonadotrophins in the ovary.
•	 A direct influence of the GnRH agonists mediated through 
receptors in the ovary.
•	 A reduction in the metabolism of the ovary, resulting in a 
decrease in the blood flow to the ovary.
Oral contraceptives also may reduce gonadotrophic levels in 
the follicular environment, and therefore also create a similar 
environment for protection.24 
A single oocyte within a dominant follicle must develop 
for ovulation to occur during a particular menstrual cycle. 
This whole process starts when a group of primordial 
follicles starts to develop. A single follicle is selected from 
this group to eventually effect ovulation. Growing follicles 
make up less than 10% of the total number of follicles, but 
after initiation of the growth process, either ovulation or 
atresia is inevitable.25 The initial growth is independent of 
gonadotrophins.12 It is not a biologically plausible argument 
that GnRH agonists work as a protective mechanism by 
keeping follicles outside of the growth phase because the 
initial process is gonadotrophin independent. It was found 
in some interesting work that GnRH agonist receptors are 
absent in the preovulatory follicle and the corpus luteum in 
human ovarian cells. Therefore, GnRH agonist stimulation is 
not possible in the primordial and early follicular stages of 
development.26,27
A protective effect of Buserelin was demonstrated in an in 
vitro study on cultured human granulosa cells exposed to 
doxyrubicine chemotherapy.28 This study provided support 
for the protective action of GnRH agonists on stromal cell 
damage. Doxorubicin caused irreversible decreases in 
oestrogen production, but the addition of GnRH agonists 
before or during treatment protected the granulosa cells. 
The cortex of the ovary is a relatively avascular area, and 
GnRH agonist downregulation owing to a lack of pituitary 
stimulation may further reduce blood flow in the ovary. 
Ultrasound studies have confirmed reduced perfusion 
during diminished pituitary function.29,30 By reducing blood 
flow, the exposure of follicles to harmful chemotherapy 
may be decreased. However, there is conflicting evidence 
that ovarian perfusion may not significantly change after 
treatment with GnRH agonists, when measured by a Doppler 
study. Significant changes in antral follicle count, stromal 
blood flow or ovarian volume were not demonstrated in a 
three-dimensional Doppler study on 85 women treated with 
short-term Buserelin.31
GnRH agonists may upregulate the production of 
antiatoptotic molecules, such as sphingosine 1-phosphate.32 
They may also affect molecules, such as transforming growth 
factor beta (TGF-β).33 Other growth factors in the TGF-β 
superfamily may also be influenced by GnRH analogues. 
However, the complex interaction of all these growth factors 
is difficult to measure and control in an experimental model. 
Some work suggests that the transition from the primordial 
to the primary follicle may be influenced by ligands produced 
by growing follicles.34 Through this secondary pathway, 
downregulation of the growing follicles by an absence of 
follicle-stimulating hormone (FSH) stimulation may lead to a 
reduced number of follicles being recruited.
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Clinical studies on ovarian suppression and 
protection against chemotherapy-induced 
ovarian damage
A review published in 2008 on the topic of ovulation 
suppression to protect against chemotherapy-induced 
ovarian toxicity and amenorrhoea concluded that the 
currently available information in the literature is not enough 
for a definite conclusion to be drawn that GnRH agonists 
are beneficial in protecting against chemotherapy-induced 
damage.33 The authors argue that on the basis of the current 
evidence, it is possible to draw the wrong conclusions. 
There are many drawbacks to the published studies, which 
are summarised in Table I. Very often, the studies were not 
controlled or historical controls were used. There were 
many treatment protocols, many different indications for 
chemotherapy, and the definition of ovarian function was 
not always the same. Various parameters were included, like 
the presence or absence of menstruation, hormone levels, 
the ultrasound appearance of the ovaries, and even cycle 
regularity. A clear indication of what is meant by “preserved 
ovarian function” and “ovarian failure” is not given in most of 
the published data.
There were unexpectedly high incidences of POF in the 
control group in two larger studies by Castelo-Branco 
et al and Huser et al.46,47 The expected rate of POF in the 
population not treated with GnRH agonists is usually in the 
region of 32-37%, as found in other studies on Hodgkin’s 
lymphoma survivors.50,51 The high POF rate in the control 
group in the two larger studies influences any meta-analysis 
currently performed. 
A slightly more positive conclusion was recorded in another 
review published in the same journal.52 However, the authors 
also concluded their review by stating that there was not 
enough convincing statistical evidence concerning the 
reduction of POF when treating young women with GnRH 
agonists. More large prospective randomised studies are 
needed.
Thirty-nine patients received GnRH and 39 chemotherapy 
only in a prospective randomised study on 80 patients with 
breast cancer.48 The rate of POF was significantly lower in the 
treatment arm of the study. This study used goserelin for 
ovarian suppression, while previous work with Buserelin was 
not beneficial. It is argues that Buserelin may perhaps not 
adequately suppress pituitary function, and this may explain 
the difference in outcome.
A study from Italy evaluated ovarian reserve in 29 patients 
treated for Hodgkin’s disease.45 The serum levels of FSH, 
luteinising hormone (LH), inhibin B, anti-Mullerian hormone 
(AMH) and the ultrasound antral follicular count were used 
as markers of ovarian reserve after chemotherapy. The 
patients were randomly given or not given GnRH agonists 
at the time of chemotherapy. It is not clear from the article 
which specific analogue was used. None of the 14 women 
who received an GnRH agonist developed amenorrhoea. 
Seven of the 15 (46%) who did not receive a GnRH agonist 
showed the clinical symptoms of ovarian failure, “suggesting 
the possible protective action of GnRH agonists”. However, 
when the results of the ovarian reserve parameters were 
compared, those treated with a GnRH agonist had similar 
results. 
A different Italian group treated 61 women with triptorelin 
monthly during chemotherapy for patients with Hodgkin’s 
lymphoma.53 The majority (81%) recovered normal menses, 
while 6% had irregular cycles. The remaining 12% had 
premature ovarian failure. The authors felt confident enough 
about the results to recommend that all young women 
should receive GnRH agonist co-treatment from the onset 
of chemotherapy.
A report from Korea investigated the incidence of 
chemotherapy-related amenorrhoea in premenopausal 
women with breast cancer.54 Two hundred and thirty-eight 
women out of a total of 326 received adjuvant endocrine 
therapy for oestrogen and progesterone receptor positivity. 
The adjuvant endocrine therapy included selective 
ooestrogen-receptor modulators (toremifene citrate and 
tamoxifen), aromatase inhibitors (letrozole and anastrozle), 
Table I: The incidence of ovarian failure in different studies with and 
without gonadotrophin-releasing hormone agonist administration
References GnRH 
agonist (%)
Control (%) Follow-up  
(years)
Waxman et al35 50.0 67.0 2.3
Blumenfeld et al36 0.0 66.0 -
Pereyra Pacheco 
et al37 




Franke, Smit and 
Vermes39 
20.0 - < 1.0
Dann et al40 0.0 17.0 5.3
Somers et al41 5.0 30.0 -
Elis et al42 0.0 8.7 -
Del Mastro et al43 3.0 - 1.0
Recchia et al44 33.0 6.3




Blumenfeld et al24 3.0 37.0 8.0
Huser et al47 21.0 71.0 1.0
Badawy, Elnashar, 
El-Ashry, Shahat48 
11.0 67.0 < 1.0
Gerber et al49 0.0 0.0 2.0
GnRH: gonadotrophin-releasing hormone
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and LH-releasing hormone. The two important predictors 
for amenorrhoea were older age at treatment and the use 
of endocrine treatment. Interestingly “the use of adjuvant 
endocrine therapy was more likely to result in permanent 
chemotherapy-related amenorrhoea, than no use” (p-value 
0.006).
The German Hodgkin Study Group prematurely stopped a 
prospective study on hormonal treatment with combined 
oral contraception or GnRH owing to a lack of effectiveness. 
The AMH levels after 12 months showed no benefit of GnRH 
or combined oral contraception.55
A meta-analysis of nine studies that included data on 366 
women found a 68% increase in the rate of preserved 
ovarian function in those women receiving a GnRH agonist.56 
Similarly, a Cochrane review came to the conclusion that 
intramuscular or subcutaneous GnRH agonists seemed “to 
be effective in protecting ovaries during chemotherapy.” 57 
Potential problems with gonadotrophin-
releasing hormone agonist treatment
Treatment with GnRH agonists is not without complications. 
The side-effects include postmenopausal symptoms, such 
as hot flushes and decreased bone mineral density. It is 
also of importance to note that GnRH receptors have been 
found in certain tumour cell lines, and the effects that GnRH 
agonists may have on tumour progression have not been 
studied carefully.21,58 
Additional potential benefits of 
gonadotrophin-releasing hormone 
treatment
GnRH agonists may be beneficial in patients with early 
receptor-positive breast carcinoma, where the suppression 
of oestrogen production could lead to a better outcome. It 
was found in a recent Cochrane review on GnRH agonists 
in an adjuvant therapy setting for early breast cancer in 
premenopausal women that the therapy may be of clinical 
benefit. The authors concluded that the current data strongly 
support the continuation of further trials on LH-releasing 
hormone agonists in early breast cancer treatment.59 
Other potential benefits of GnRH agonists unrelated to 
ovarian function include a reduction in menorrhagia 
during chemotherapy, especially at the time when 
myelosuppression may be an important complication of 
chemotherapy. A systematic review found that GnRH agonist 
therapy is highly effective in preventing excessive uterine 
bleeding in the treatment of haematological malignancies.60
Hormonal contraceptives 
The suppression of follicle development during the 
administration of chemotherapy may reduce the risk 
of follicular damage. A group of 31 young women who 
received neoadjuvant chemotherapy for the treatment of 
osteosarcoma were observed for chemotherapy-induced 
menopause.61 All of these patients received high-dose 
ifosfamide, methrotrexate, adriamycin and cisplatinum, and 
were treated with oral contraceptives for the duration of 
chemotherapy.
Three of the 19 patients in the treatment group developed 
early menopause. They were compared with a historical 
control group, in which three of the 71 patients developed 
chemotherapy-induced menopause. The authors concluded 
that oral contraceptives during chemotherapy do not 
protect ovarian function in patients receiving high-dose 
alkylating chemotherapy, and that the age at treatment and 
the total dose of alkylating agents are the most important 
predictors of ovarian failure.61 
An earlier retrospective report on the reproductive outcome 
of women treated for Hodgkin’s disease included a total 
of 44 women followed-up after chemotherapy [mustine, 
vinblastine, procarbazine and prednisolone (MVPP)].6 
Nine of these patients took combined oral contraceptives 
throughout the administration of chemotherapy, of whom 
four subsequently developed amenorrhoea, and three more 
oligomenorrhoea. It appears as if oral contraceptives did 
not protect these patients against chemotherapy-induced 
ovarian damage. 
A report published in 1981 evaluated the use of oral 
contraceptives in six young women treated with MVPP 
for Hodgkin’s disease.62 They were followed-up between 
four and 12 months, and underwent post-therapy ovarian 
biopsies and menstrual history to determine their fertility 
potential. Five of the six patients had normal menstruation 
after discontinuation of the chemotherapy. The three cases 
who underwent ovarian biopsies were aged 18, 19 and 
28 years, respectively. The 19-year-old woman had more 
than 1 000 follicles per section after chemotherapy. It is 
difficult to know whether or not a histological evaluation of 
follicle numbers can predict eventual menstrual function, 
but despite the small numbers in this study, the authors 
concluded “that the suppression of ovarian function by 
combined oral contraceptives protects the ova against 
otherwise certain injury by the chemotherapeutic drugs”.62
A group from Israel reported on the post-treatment fertility 
status of women after receiving aggressive treatment for 
non-Hodgkin’s lymphoma. It was found that age was the 
most important risk factor. Older women were at the highest 
risk of chemotherapy-related amenorrhoea.42 Fertility-
preserving measures, in the form of GnRH agonists, were 
used in three patients and nine received combined oral 
contraceptives. When the patients who received ovarian 
suppression were compared to the rest of the group, a 
significant difference in the rate of ovarian failure was not 
found. 
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The best evidence, so far, for the potential benefit of oral 
contraceptives during chemotherapy derives from a large 
retrospective report from Germany.63 A total of 405 women 
answered a questionnaire on their menstrual status after 
therapy for Hodgkin’s lymphoma. These patients were 
all aged 40 years and younger at treatment. The rate of 
amenorrhoea was significantly higher in women not taking 
oral contraceptives, compared to that in the women on oral 
contraceptives during chemotherapy (44.1% versus 10.1%) 
(p-value < 0.0001). A multivariate analysis was performed, 
including age, chemotherapy regime, stage of disease, the 
use of oral contraceptives during chemotherapy and the 
effect on amenorrhoea. 
There was enough information on 214 women, from a total 
of 405, for them to be included in the multivariate analysis, 
and the following were found to be significant predictors of 
amenorrhoea:
•	 Receiving eight cycles of dose-escalated bleomycin, 
etoposide, adriamycin (doxorubicin), cyclophosphamide, 
oncovin (vincristine), procarbazine and prednisone 
(BEACOPP), when compared to other less toxic regimes.
•	 Amenorrhoea was statistically significantly higher in 
women with advanced stage cancer (p-value < 0.0001).
•	 Being older than 30 years of age at treatment (p-value 
0.0065).
•	 Not taking oral contraceptives during chemotherapy 
(p-value 0.0002).
This study provides the strongest evidence so far for the 
potential positive effect of oral contraceptives during 
chemotherapy. 
However, oral contraceptives have never been adequately 
tested in a randomised controlled trial.64 A randomised phase 
II trial performed by the German Hodgkin Study Group, the 
PROtecting Ovaries and Fertility During Chemotherapy 
(PROOF), that evaluated the use of GnRH agonists and oral 
contraceptives in patients receiving treatment for Hodgkin’s 
lymphoma, was stopped early after only 23 patients 
enrolled. The reason for the early termination of the study 
was mainly because most women had already received 
GnRH analogues, as recommended by their gynaecologists. 
Twelve patients received oral contraceptives and 11 GnRH 
analogues. The respective infertility rates were 90% for 
contraceptives and 100% with the GnRH agonists. The 
conclusion of the authors was that treatment with GnRH 
agonists or oral contraceptives conferred no meaningful 
ovarian protection. 
Medroxiprogesterone acetate
The only report on the effect of medroxyprogesterone 
acetate on ovarian protection during chemotherapy derives 
from a small descriptive study from Italy.65 Twelve women 
were included, of whom four received no chemotherapy 
or MPA, four received no chemotherapy and 250 mg MPA, 
and the last four received chemotherapy and 250 mg MPA 
per month. Ovarian biopsies were taken, and electron 
microscopy studies performed. Despite the very small 
number of cases, this did not prevent the authors from 
stating that “the results presented here demonstrate that 
the administration of MPA to patients with Hodgkin’s disease 
protects the ovary against an acute effect of chemotherapy”. 
It is not clear from the discussion how the authors concluded 
that there was a protective effect because the studied 
follicles of patients receiving chemotherapy and MPA had 
substantial morphological damage. At present, there is no 
strong argument in the literature to suggest a protective 
effect of MPA against chemotherapy-induced amenorrhoea.
Conclusion
It is very difficult to reach a conclusion on the use of ovarian 
suppression during chemotherapy in an attempt to prevent 
subsequent chemotherapy-induced ovarian failure. Most of 
the available evidence in the literature derives from non-
randomised case reports, often with historical controls or 
no controls. Various chemotherapy regimens were used, the 
doses of GnRH agonists and combined oral contraceptives 
were not similar, and in general, the number of patients 
was low. Also, a randomised controlled trial has not been 
conducted to evaluate combined oral contraceptives in this 
clinical scenario. The authors of a Cochrane review were 
cautious when concluding that GnRH analogues seemed “to 
be effective”, but recommended that they should be given 
before or during treatment.57
The only way to reach consensus would be to test combined 
oral contraceptives and GnRH agonists in properly designed, 
large, prospective randomised trials. The numbers of young 
patients with cancer are usually low in individual institutions, 
and it is important to combine data from multiple sites to 
obtain useful results.
At present, the indication for oral contraceptives or GnRH 
agonists may be stronger for other non-fertility benefits. 
GnRH agonists and oral contraceptives may be used to 
reduce menstrual blood loss, which is often increased 
during treatment because of abnormal clotting and 
platelet function. When hormones are contraindicated 
owing to hormone-sensitive tumours, GnRH agonists can 
be very useful. There is some evidence that GnRH agonist 
administration may improve the outcome in oestrogen 
receptor-positive breast carcinoma.
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